Richney, chairman is apparently in UK progressing talks with a confidential partner that I'm assuming will assist with the selling their product(s) to a UK market (approval obtained already) with up to 6 million asthma sufferers. If they obtain FDA approval we are talking about a potential US market with up to 25 million asthma sufferers. (10% being children). Combine all these markets together and Australia's, the companies growth potential than becomes the attraction to investors. The delays, eating up of funds and the lack of more announcements is hurting the share price. Based on previous announcements I would be surprised if they did not obtain FDA approval, the uncertainty is the timing. The company reports its yearly result in a few weeks time. Hopefully they will have more news on how they are progressing with launches/approvals/partnership deals.
ISN Price at posting:
16.0¢ Sentiment: Hold Disclosure: Held
